The FDA has unveiled draft guidance that could help speed up the development of genome editing therapies by allowing companies to make greater use of existing scientific knowledge.
New guidance
Released on 2 June, the document permits sponsors to build on data generated from previous programmes, rather than repeating studies from scratch. The approach could prove particularly valuable in rare diseases, where patient populations are small and development costs remain high.
Under the proposal, companies may be able to rely on existing manufacturing, nonclinical and clinical knowledge if they can show it is relevant to the therapy under development. This could include analytical testing methods, manufacturing controls, stability data and experience gained from similar genome editing platforms.
The draft guidance comes as the field becomes a larger part of the biotech landscape in the US. According to Healthcare Foresights, North America accounted for 44% of the global genome editing market in 2025, positioning it as the market leader.
FDA rationale
By launching the proposal, the FDA hopes to reduce unnecessary duplication and help promising therapies reach patients more efficiently.
“Today’s action reflects the FDA’s commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options,” said Karim Mikhail, Acting Director, Center for Biologics Evaluation and Research.
The document forms part of a wider FDA push to overhaul advanced therapies approvals. However, the agency stressed that sponsors will still need to provide product-specific evidence and outline a scientific rationale for any data they choose to leverage.
“Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy,” said Vijay Kumar, Acting Director, Office of Therapeutic Products.
The draft guidance is open for public comment for 90 days before being finalised.
Featured image: adragan on Adobe Stock
